Clinical trial · Observational
Cervical Cancer Susceptible Population Classification
Evalutaion of the SNPs Test in Average Cervical Cancer Screening Episode
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cervical cancer is the third most common lethal tumor globally, causing around a quarter million deaths annually, despite the availability of HPV vaccines. Recent Genome-wide association studies (GWAS) have identified numerous genetic markers linked to cervical cancer, including rs10175462, rs10007915, rs35721900, and rs61646675, which have been verified as being related to susceptibility to cervical cancer. However, many reports lack clarity, consistency, and validation. In this comprehensive study, we will analyze the genomic risk factors associated with cervical cancer, classify individuals into different risk categories, and explore potential biomarkers and therapeutics.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer Susceptible Population Classification | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PCR and sequence | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (4)
- label
- Normal
- description
- HPV negative， TCT negative
- interventionNames
- Genetic: PCR and sequence
- label
- LSIL
- description
- HPV postive, TCT: CIN I or Colposcopy LSIL
- interventionNames
- Genetic: PCR and sequence
- label
- HSIL
- description
- HPV postive, TCT: CIN II-III or Colposcopy HSIL
- interventionNames
- Genetic: PCR and sequence
- label
- cervical cancer
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Subjects aged \>=18 years at time of consent 2. Intended to undergo screening colposcopy 3. Considered by a physician or healthcare provider as being of "average risk" for cervical cancer 4. Willing to consent to blood draw cervical disease treatments 5. Willing to sonsent to follow-up for five years as per protocol Exclusion Criteria: 1. History of cervical cancer 2. History of any malignancy (patients who have undergone surgical removal of skin squamous cell cancer may be enrolled provided the procedure was completed at least 12 months prior to the date of provision of informed consent for the study) 3. Currently taking any anti-neoplastic or disease-modifying anti-rheumatic drugs. 4. Any major physical trauma (e.g. disruption of tissue, surgery, organ transplant, blood product transfusion) within the 30 days leading up to the provision of informed consent 5. Known medical condition which, in the opinion of the investigator, should preclude enrollment into the study
References
Publications (0)
Data not yet available